Improving chemotherapy and immunotherapy for pancreatic cancer using light activation
Molecular Imaging Guidance for Potentiating Chemoimmunotherapy in Pancreatic Cancer using Photodynamic Priming
This study is exploring a new way to make chemotherapy and immunotherapy work better for people with pancreatic cancer by using light to activate a special treatment that helps the drugs reach the tumor more effectively and boosts the immune response, all while using advanced 3D models to improve the approach.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project ID | NIH-11122217 on NIH RePORTER |
What this research studies
This research investigates a novel approach to enhance the effectiveness of chemotherapy and immunotherapy in patients with pancreatic cancer. It utilizes a technique called photodynamic priming, which involves using light to activate a non-toxic treatment that helps improve drug delivery and counteracts the tumor's immunosuppressive environment. By addressing the challenges posed by desmoplasia, this method aims to increase the response rates to existing treatments, potentially leading to better patient outcomes. The research will involve advanced 3D modeling to understand the tumor environment and optimize treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with locally advanced or metastatic disease.
Not a fit: Patients with resectable pancreatic cancer or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment responses for patients with pancreatic cancer.
How similar studies have performed: While the approach of using photodynamic therapy is established, its application in enhancing chemo-immunotherapy for pancreatic cancer is novel and has not been extensively tested.
Where this research is happening
Richardson, United States
- University of Texas Dallas — Richardson, United States (Active)
Researchers
- Principal investigator: Obaid, Girgis — University of Texas Dallas
- Study coordinator: Obaid, Girgis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.